背景:阿尔茨海默病(AD)是老年人最常见的疾病之一,痴呆症的发病率很高。AD的发病机制复杂,临床上尚无统一的结论和有效的治疗方法。近年来,随着中医药的发展,研究者根据中医多靶点的特点,提出了以中医为基础防治AD的思路。阿魏酸(FA),也称为3-甲氧基-4-羟基肉桂酸,是中药中的活性成分,抑制β-淀粉样蛋白(Aβ)聚集,具有抗氧化和抗炎作用。据报道,FA衍生物具有低毒性,高生物活性,血脑屏障通透性高.然而,尚未系统地阐明FA在AD治疗中的多靶点。
目的:在这篇系统综述中,我们旨在全面评估FA及其衍生物对体外和体内AD模型的神经保护作用。
方法:我们搜索了PubMed,中国国家知识基础设施(CNKI),百度学术,和万方数据库,用于相关临床前研究,直至2021年11月。
结果:我们确定了使用相关关键词评估FA及其衍生物疗效的研究。包括864项研究,其中129个是在PubMed中发现的,111在CNKI,454在百度学术,万方170人。由于数据库之间的重复,在应用排除和纳入标准后,选择了43篇文章。此后,回顾了43篇文章的摘要。最后,这篇综述包括21篇文章,包括11个体内,5在体外,5体内和体外研究。
结论:先前的研究表明,FA或其衍生物对AD模型具有多种治疗作用,并能改善AD的症状和AD细胞模型的耐药性。FA及其衍生物具有抗Aβ聚集作用,抗氧化剂,抗炎,和其他作用,是多靶向治疗AD的潜在药物。我们的研究结果表明,FA及其衍生物对AD的动物和细胞模型具有显著的治疗作用,提示它们可能是AD患者的潜在治疗药物。
BACKGROUND: Alzheimer\'s disease (AD) is one of the most common diseases in the elderly, with a high incidence of dementia. The pathogenesis of AD is complex, and there is no unified conclusion and effective treatment in the clinic. In recent years, with the development of traditional Chinese medicine (TCM), researchers put forward the idea of prevention and treatment of AD based on TCM according to the characteristics of multi- target of TCM. Ferulic acid (FA), also known as 3-methoxy-4-hydroxycinnamic acid, is an active ingredient in TCM that inhibits β-amyloid (Aβ) aggregation and has antioxidant and anti-inflammatory effects. FA derivatives have been reported to have low toxicity, high biological activity, and high blood-brain barrier permeability. However, the multitarget of FA in the treatment of AD has not been systematically elucidated.
OBJECTIVE: In this systematic
review, we aimed to comprehensively assess the neuroprotective effects of FA and its derivatives on in vitro and in vivo AD models.
METHODS: We searched PubMed, Chinese National Knowledge Infrastructure (CNKI), Baidu Academic, and Wanfang databases for relevant pre-clinical studies until November 2021.
RESULTS: We identified studies that evaluated the efficacy of FA and its derivatives using relevant keywords. 864 studies were included, of which 129 were found in PubMed, 111 in CNKI, 454 in Baidu Academic, and 170 in Wanfang. Due to duplication between databases, and after applying the exclusion and inclusion criteria, 43 articles were selected. Thereafter, the abstracts of the 43 articles were reviewed. Finally, 21 articles were included in this
review, including 11 in vivo, 5 in vitro, and 5 in vivo and in vitro studies.
CONCLUSIONS: Previous studies have shown that FA or its derivatives have multiple therapeutic effects on AD models and can improve the symptoms of AD and resistance of AD cell models. FA and its derivatives have anti-Aβ aggregation, antioxidant, antiinflammatory, and other effects and are potential drugs for the multi-targeted treatment of AD. The result of our study showed that FA and its derivatives have significant therapeutic effects on animal and cell models of AD, suggesting that they may be potential therapeutic drugs for patients with AD.